Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. eye opening
Show results for
Products
Services
Software

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Eye Opening Articles & Analysis

21 news found

5 Ways OCT Technology Can Benefit Your Practice

5 Ways OCT Technology Can Benefit Your Practice

The human eye is an amazing organ. With the fastest muscle in your body, it contains 107 million cells and can differentiate approximately 10 million colors. ...

ByLombart Instrument, Inc.


Reflow Medical Completes DEEPER LIMUS Clinical Trial Enrollment

Reflow Medical Completes DEEPER LIMUS Clinical Trial Enrollment

“We were impressed from the start with the acute luminal gain we were able to achieve,” says Marianne Brodmann, MD, who is a Professor and Vascular Specialist at the Medical University of Graz, Austria, and the Principal Investigator for the study. “It’s eye-opening, how the vessel responds. The device is also intuitive and easy to ...

ByReflow Medical, Inc.


Sight Sciences Reports First Quarter 2022 Financial Resultsgrafic lines 4 Sight S

Sight Sciences Reports First Quarter 2022 Financial Resultsgrafic lines 4 Sight S

Recent Business Highlights Generated first quarter 2022 total revenue of $14.9 million, an increase of 72% compared to the prior year period Increased the number of facilities ordering the OMNI® Surgical System from 760 in the fourth quarter of 2021 to 811 in the first quarter of 2022, and the installed base of TearCare® facilities from 562 on December 31, 2021 to 635 on March 31, ...

BySight Sciences, Inc.


Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI® Surgical System in Pseudophakic Eyes with Open-Angle Glaucoma

Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI® Surgical System in Pseudophakic Eyes with Open-Angle Glaucoma

(Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced that the first patient has been treated in the novel TRIDENT clinical trial, designed to demonstrate the OMNI Surgical System with higher volume as a safe and effective standalone treatment option, compared to implantation of iStent ...

BySight Sciences, Inc.


Our Alliance with Serum Institute Provides an Accelerated Entry into Vaccines

Our Alliance with Serum Institute Provides an Accelerated Entry into Vaccines

Our pioneering efforts in the development of biosimilar insulins and monoclonal antibodies have enabled us to serve several million patients in both developed and developing countries in chronic or non-communicable disease segments such as diabetes, cancer and auto-immune disorders. The COVID-19 pandemic has opened our eyes to the serious threat posed by viral ...

ByBiocon


Sight Sciences Receives FDA 510(k) Clearance of the TearCare System for Treatment of Meibomian Gland Dysfunction (MGD), the Leading Cause of Dry Eye Disease

Sight Sciences Receives FDA 510(k) Clearance of the TearCare System for Treatment of Meibomian Gland Dysfunction (MGD), the Leading Cause of Dry Eye Disease

Present in the vast majority of DED cases, MGD is largely undertreated, with no insured treatment options currently available that can address MGD as the root cause of dry eye. Meibum, a clear, oily secretion that is expressed through the eye’s meibomian glands, works to coat the outermost layer of the eye and protect tears from premature ...

BySight Sciences, Inc.


Ivantis Announces First Patient Enrolled in Pivotal Clinical Trial Evaluating the Hydrus Microstent in Standalone MIGS for Mild to Moderate Glaucoma

Ivantis Announces First Patient Enrolled in Pivotal Clinical Trial Evaluating the Hydrus Microstent in Standalone MIGS for Mild to Moderate Glaucoma

Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, today announced that the first patient has been enrolled in a pivotal clinical trial evaluating the Hydrus Microstent in patients with mild to moderate open-angle ...

ByIvantis, Inc.


Hydrus Microstent Lowers Visual Field Loss by 47% According to New 5-Year Pivotal Trial Data

Hydrus Microstent Lowers Visual Field Loss by 47% According to New 5-Year Pivotal Trial Data

Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, has announced new data from its five-year HORIZON pivotal trial showing that the Hydrus Microstent lowers the rate of visual field loss by 47% versus cataract surgery alone. ...

ByIvantis, Inc.


World Thrombosis Day

World Thrombosis Day

On World Thrombosis Day, October 13, 2021, Emosis is proud to be a "messenger" of the "Eyes open to Thrombosis" information campaign. Eyes open to Thrombosis WTD is an educational campaign to raise awareness and educate the public to the importance of reducing death and disability from thrombosis. ...

ByEmosis Diagnostics SAS


Ivantis Announces Settlement of Glaukos Patent Litigation

Ivantis Announces Settlement of Glaukos Patent Litigation

Ivantis, Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, today announced that it has entered into an agreement with Glaukos Corporation to settle and dismiss all pending global litigation between them. ...

ByIvantis, Inc.


Hydrus Microstent Now First MIGS Device Proven With 5-Year Pivotal Trial Data; Results Show Over 60% Reduction in Secondary Glaucoma Surgeries, Sustained Reduction in Medication Use

Hydrus Microstent Now First MIGS Device Proven With 5-Year Pivotal Trial Data; Results Show Over 60% Reduction in Secondary Glaucoma Surgeries, Sustained Reduction in Medication Use

Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, announced today the first-ever release of five-year follow-up data from its HORIZON pivotal trial. ...

ByIvantis, Inc.


Hydrus Microstent Receives Highest Designation of Any MIGS Device as Part of AAO Treatment Guidelines

Hydrus Microstent Receives Highest Designation of Any MIGS Device as Part of AAO Treatment Guidelines

Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, announced today that the American Academy of Ophthalmology (AAO) has designated the Hydrus Microstent as “Level 1, Moderate Quality, Strong Recommendation” — the highest ...

ByIvantis, Inc.


First-Ever Four-Year MIGS Pivotal Trial Results Show Hydrus Microstent Significantly Reduces Need for Invasive Surgery and Subsequent Glaucoma Medication

First-Ever Four-Year MIGS Pivotal Trial Results Show Hydrus Microstent Significantly Reduces Need for Invasive Surgery and Subsequent Glaucoma Medication

Ivantis, Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, announced today the first-ever, four-year follow-up data for a MIGS device in an FDA pivotal trial. ...

ByIvantis, Inc.


Seno Medical: Making a Difference for Breast Cancer in San Antonio

Seno Medical: Making a Difference for Breast Cancer in San Antonio

As a man, while I understand the struggle and recognize breast cancer has been a challenging event in a patient’s life, I’ve never walked a mile in her shoes and I don’t know many that have. This program opened my eyes and helped me better understand how important it is – what we do here at Seno ...

BySeno Medical Instruments, Inc.


Did you see MAXCOM at the Clean Med Expo?

Did you see MAXCOM at the Clean Med Expo?

Karan Singh attended the conference and offered attendees an eye-opening view of the innovations that are to come to Maxcom that will cover chemicals that are not covered by GHS now, this includes, pharmaceutical drugs, Antineoplastic Drugs (Cytotoxic) and hazardous drugs, biohazardous materials and radioactive isotopes. ...

ByIncora


Renishaw engineers share expertise to increase pupils’ STEM skills

Renishaw engineers share expertise to increase pupils’ STEM skills

” Renishaw is a leading engineering company involved in a large number of outreach projects to encourage children and young people to participate in engaging STEM activities and open their eyes to STEM careers. This includes work with Greenpower, Young Engineers, Bristol Music Trust and work experience weeks awarded full recognition by the Skills for ...

ByRenishaw plc


Eye on Earth First User Conference: A real eye opener

The aim of the conference was to bring together the Eye on Earth partners and communities to create a widespread understanding among data providers and users about the concept of data and information sharing through the Eye on Earth Network. ...

ByEuropean Environment Agency (EEA)


GREENGUARD Expands Presence in Global and North American Consumer Marketplace

GREENGUARD Expands Presence in Global and North American Consumer Marketplace

And, because their brains, lungs, and other vital organs are still developing, children are particularly susceptible to eye, nose, and throat irritation; headaches; nausea; wheezing; coughing; dizziness; and general malaise. ...

ByGREENGUARD Environmental Institute


Possible MRSA Outbreak at Popular Arizona Pool

Possible MRSA Outbreak at Popular Arizona Pool

Back in 2009, a researcher from the University of Washington presented results from an eye opening study to the American Society for Microbiology Conference. ...

ByEMSL Analytical, Inc.


Why nobody (really) cares how many hours your employees volunteered

Why nobody (really) cares how many hours your employees volunteered

Despite these sentiments, a recent report in the UK provides the following, eye-opening info: "most managers confess not knowing how to measure the benefits of volunteering was a barrier to encouraging employees to take part ...

By3BL Media

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT